Organon Financial Statements (OGN)
|
|
|
|
Report date
|
|
|
31.12.2019 |
31.12.2020 |
21.03.2022 |
27.02.2023 |
26.02.2024 |
|
01.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
7 777 |
8 096 |
6 304 |
6 174 |
6 263 |
|
6 409 |
|
Operating Income, bln rub |
|
|
3 847 |
2 849 |
1 619 |
1 478 |
1 329 |
|
1 502 |
|
EBITDA, bln rub |
? |
|
4 180 |
2 989 |
1 814 |
1 690 |
1 436 |
|
1 687 |
|
Net profit, bln rub |
? |
|
3 218 |
2 160 |
1 351 |
917.0 |
1 023 |
|
1 301 |
|
|
OCF, bln rub |
? |
|
2 767 |
2 187 |
2 458 |
858.0 |
799.0 |
|
397.5 |
|
CAPEX, bln rub |
? |
|
92.0 |
278.0 |
488.0 |
427.0 |
261.0 |
|
266.9 |
|
FCF, bln rub |
? |
|
2 675 |
1 909 |
1 970 |
431.0 |
538.0 |
|
316.4 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
145.0 |
290.0 |
294.0 |
|
296.0 |
|
|
Ordinary share dividend yield, %
|
|
|
|
|
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
10.7% |
31.6% |
28.7% |
|
22.8% |
|
|
OPEX, bln rub |
|
|
1 663 |
1 970 |
2 111 |
2 175 |
2 419 |
|
2 232 |
|
Cost of production, bln rub |
|
|
2 274 |
3 347 |
2 382 |
2 294 |
2 515 |
|
2 675 |
|
R&D, bln rub |
|
|
220.0 |
304.0 |
443.0 |
471.0 |
528.0 |
|
473.0 |
|
Interest expenses, bln rub |
|
|
6.00 |
6.00 |
258.0 |
422.0 |
527.0 |
|
517.0 |
|
|
Assets, bln rub |
|
|
10 548 |
10 434 |
10 681 |
10 955 |
12 058 |
|
12.8 |
|
Net Assets, bln rub |
? |
|
7 035 |
-820.0 |
-1 508 |
-892.0 |
-70.0 |
|
493.0 |
|
Debt, bln rub |
|
|
104.0 |
31.0 |
9 134 |
8 913 |
8 760 |
|
8 749 |
|
Cash, bln rub |
|
|
319.0 |
500.0 |
737.0 |
706.0 |
693.0 |
|
0.763 |
|
Net debt, bln rub |
|
|
-215.0 |
-469.0 |
8 397 |
8 207 |
8 067 |
|
8 748 |
|
|
Ordinary share price, rub |
|
|
|
|
30.5 |
27.9 |
14.4 |
|
30.5 |
|
Number of ordinary shares, mln |
|
|
253.1 |
253.5 |
253.6 |
254.1 |
255.2 |
|
257.5 |
|
|
Market cap, bln rub |
|
|
0 |
0 |
7 721 |
7 097 |
3 681 |
|
7 854 |
|
EV, bln rub |
? |
|
-215 |
-469 |
16 118 |
15 304 |
11 748 |
|
16 602 |
|
Book value, bln rub |
|
|
1 863 |
-5 926 |
-6 762 |
-6 144 |
-5 206 |
|
488 |
|
|
EPS, rub |
? |
|
12.7 |
8.52 |
5.33 |
3.61 |
4.01 |
|
5.05 |
|
FCF/share, rub |
|
|
10.6 |
7.53 |
7.77 |
1.70 |
2.11 |
|
1.23 |
|
BV/share, rub |
|
|
7.36 |
-23.4 |
-26.7 |
-24.2 |
-20.4 |
|
1.89 |
|
|
EBITDA margin, % |
? |
|
53.7% |
36.9% |
28.8% |
27.4% |
22.9% |
|
26.3% |
|
Net margin, % |
? |
|
41.4% |
26.7% |
21.4% |
14.9% |
16.3% |
|
20.3% |
|
FCF yield, % |
? |
|
|
|
25.5% |
6.07% |
14.6% |
|
4.03% |
|
ROE, % |
? |
|
45.7% |
-263.4% |
-89.6% |
-102.8% |
-1 461% |
|
263.9% |
|
ROA, % |
? |
|
30.5% |
20.7% |
12.6% |
8.37% |
8.48% |
|
10 202% |
|
|
P/E |
? |
|
0.00 |
0.00 |
5.71 |
7.74 |
3.60 |
|
6.04 |
|
P/FCF |
|
|
0.00 |
0.00 |
3.92 |
16.5 |
6.84 |
|
24.8 |
|
P/S |
? |
|
0.00 |
0.00 |
1.22 |
1.15 |
0.59 |
|
1.23 |
|
P/BV |
? |
|
0.00 |
0.00 |
-1.14 |
-1.16 |
-0.71 |
|
16.1 |
|
EV/EBITDA |
? |
|
-0.05 |
-0.16 |
8.89 |
9.06 |
8.18 |
|
9.84 |
|
Debt/EBITDA |
|
|
-0.05 |
-0.16 |
4.63 |
4.86 |
5.62 |
|
5.19 |
|
|
R&D/CAPEX, % |
|
|
239.1% |
109.4% |
90.8% |
110.3% |
202.3% |
|
177.2% |
|
|
CAPEX/Revenue, % |
|
|
1.18% |
3.43% |
7.74% |
6.92% |
4.17% |
|
4.16% |
|
| Organon shareholders |
